Search Within

Michael John Mauro

  1. "Elsevier Inc."
Formats
  1. Meeting Abstract (41)
  2. Journal Article (6)
Groups
  1. Adult Leukemia (47)
  2. Center for Hematologic Malignancies (47)
  3. Department of Medicine (47)
  4. Hematologic Malignancies, Division of (47)
  5. Biostatistics Service (1)
  6. Bone Marrow Transplant (1)

More Groups

People
  1. Ellin Berman (2)
  2. Alexander Geyer (1)
  3. Boglarka Gyurkocza (1)
  4. Esperanza Papadopoulos (1)
  5. John Vaughn (1)
  6. Martin Tallman (1)

More People

Years
  1. 2024 (1)
  2. 2023 (5)
  3. 2022 (7)
  4. 2021 (6)
  5. 2020 (4)
  6. 2019 (5)

More Years

Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (44)
  2. Best Practice and Research: Clinical Haematology (1)
  3. Hematology/Oncology Clinics of North America (1)
  4. Transplantation and Cellular Therapy (1)
Publishers
  1. Elsevier Inc. (47)

Results (47)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dose-optimization study of 3 starting doses of ponatinib: Long-term results from the OPTIC trial
    Meeting Abstract

    Cortes, J.; Deininger, M.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Responses with asciminib continue to deepen over time in patients with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs) in the phase III ASCEMBL study
    Meeting Abstract

    Mauro, M.; Hochhaus, A.; Hughes, T.; Rea, D.; Boquimpani, C.; Minami, Y.; Apperley, J.; Garcia-Gutiérrez, V.; Kapoor, S.; Espurz, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • First-in-human phase I study of ELVN-001, an oral, selective BCR::ABL1 tyrosine kinase inhibitor, in patients with chronic myeloid leukemia who failed prior tyrosine kinase inhibitors
    Meeting Abstract

    Mauro, M.; Lang, F. B.; Kim, D. W.; Heinrich, M.; Sasaki, K.; Lyssikatos, J.; Collins, H.; Hochhaus, A.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • ASC2ESCALATE: A US, phase II open-label, single-arm, dose-escalation study of asciminib monotherapy in second-line (2L) and first-line (1L) treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP)
    Meeting Abstract

    Atallah, E.; Mauro, M.; Sasaki, K.; Levy, M.; Koller, P.; Yang, D.; Laine, D.; Sabo, J.; Gu, E. N.; Cortes, J.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Post hoc analysis of patient responses by T315I mutation status from the 3-year update of the optic trial: A dose-optimization study of 3 starting doses of ponatinib
    Meeting Abstract

    Cortes, J.; Deininger, M.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Molecular response of ≤10% BCR::ABL1IS is predictive of positive outcomes in patients with treatment-resistant chronic-phase chronic myeloid leukemia (CP-CML) treated with ponatinib from the phase 2 OPTIC trial
    Meeting Abstract

    Apperley, J.; Cortes, J.; Jabbour, E.; Hochhaus, A.; Hughes, T.; Chuah, C.; de Lavallade, H.; Deininger, M.; Lipton, J. H.; Lomaia, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Efficacy and safety results from ASCEMBL, a Phase III study of asciminib vs. bosutinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update
    Meeting Abstract

    Réa, D.; Hochhaus, A.; Mauro, M. J.; Minami, Y.; Lomaia, E.; Voloshin, S.; Turkina, A.; Kim, W.; Apperley, J. F.; Cortes, J. E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • AIM4CML Trial in progress: A phase IIIb study of asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without the T315I mutation
    Meeting Abstract

    Levy, M. Y.; Mauro, M. J.; Issa, G. C.; Andorsky, D.; Tomassetti, S.; Broun, E. R.; Maegawa, R.; Deininger, M.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • ASC2ESCALATE trial in progress: A phase 2 single-arm dose escalation study of asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase (CMLCP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)
    Meeting Abstract

    Sasaki, K.; Mauro, M. J.; Levy, M. Y.; Atallah, E. L.; Koller, P.; Maegawa, R.; Damon, A.; Kumar, J.; Khan, M.; Cortes, J. E.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Asciminib provides durable molecular responses in patients with chronic myeloid leukemia in chronic phase (CML-CP) with the T315I mutation: Updated efficacy and safety data from a phase I trial
    Meeting Abstract

    Hughes, T. P.; Cortes, J. E.; Réa, D.; Mauro, M. J.; Hochhaus, A.; Kim, D. W.; Sasaki, K.; Lang, F.; Heinrich, M. C.; Breccia, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save